Gemtuzumab Ozogamicin: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), G-BA (Germany) and NICE (England), among others, recommended or restricted gemtuzumab ozogamicin, while AOTMIT (Poland), HIRA (South Korea) and PHARMAC (New Zealand) did not recommend it.
Assessment has run over 9.5 years, from 7 May 2015 at PHARMAC (New Zealand) to 7 Nov 2024 at HIRA (South Korea).
No assessment is on file from HAS (France), TLV (Sweden) and CIPM (Spain), each among the eight highest-volume agencies here.
4 distinct indication wordings are recorded for gemtuzumab ozogamicin by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 11 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
PHARMAC (New Zealand) was first to assess gemtuzumab ozogamicin, on 7 May 2015; HIRA (South Korea) did not open a file until 7 Nov 2024 — an unusually long tail of 9.5 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 6 years in total.
Restriction is doing real work here: 3 of 9 decisive outcomes narrowed gemtuzumab ozogamicin to a subgroup rather than accepting or refusing it outright, at DMC (Denmark), G-BA (Germany) and SMC (Scotland).
PHARMAC (New Zealand) is the only agency to have returned to gemtuzumab ozogamicin, recording 2 separate entries.
10 of the 18 agencies in this archive hold a record for gemtuzumab ozogamicin.
The full ledger for gemtuzumab ozogamicin reads 3 not recommended, 3 recommended, 3 restricted and 1 other, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HIRA (South Korea) | 7 Nov 2024 | 급성골수성백혈병 | not reimbursed | source |
| PBAC (Australia) | 2021 | Acute myeloid leukaemia (AML) | Recommended | source |
| PHARMAC (New Zealand) | 12 May 2021 | For use in combination with daunorubicin and cytarabine for treatment of de novo acute myeloid leukaemia | PTAC advice: No Formal Recommendation · decision reached | source |
| AOTMIT (Poland) | 17 Aug 2020 | programu lekowego ͣLeczenie ostrej białaczki szpikowej gemtuzumabem ozogamycyny (ICD -ϭϬ CϵϮ.ϬͿ͟ w populacji Uzasadnieni… | not recommended | source |
| NYE METODER (Norway) | 22 Sep 2019 | I kombinasjon med kjemoterapi ved akutt myelogen leukemi (AML) | introduced | source |
6 further decisions for gemtuzumab ozogamicin, across 6 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- venetoclax — divergent outcome (not recommended vs recommended) on a shared indication
- midostaurin — divergent outcome (not recommended vs recommended) on a shared indication
- gilteritinib — divergent outcome (not recommended vs recommended) on a shared indication
- azacitidine — divergent outcome (not recommended vs recommended) on a shared indication
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
Coverage: 11 decisions for gemtuzumab ozogamicin from 10 agencies, 2015 to 2024. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.